Journal of Cancer Research and Clinical Oncology

, Volume 136, Issue 8, pp 1193–1199 | Cite as

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients

Original Paper



This study was performed to examine possible use of thymidine kinase 1 concentration in serum (STK1) for prognosis of non-Hodgkin’s lymphoma patients following chemotherapy treatment.


The STK1 levels of 37 patients were determined by enhanced chemiluminescent dot-blot assay on the day before chemotherapy, and on day 1 and day 28 after start of the treatment. The specificity and sensitivity was evaluated by Western blot with anti-TK1 IgY antibody and by receiver operating characteristic (ROC) analysis.


Western blot and ROC analysis of TK1 in serum showed high specificity and sensitivity. The mean STK1 level of the non-Hodgkin’s lymphoma patients was significantly higher compared to healthy persons (p < 0.001). The mean STK1 level increased significantly (p < 0.001) on day 1 and then declined, reaching on day 28 values corresponding to those of healthy persons. The mean STK1 values before treatment and at 1 and 28 days after start of the treatment also correlated significantly with the clinical response (CR, PR and NR) and five-year survival.


Although the number of patients was limited in this study, TK1 in serum might possess an important reference value in the evaluation of treatment and prognosis of non-Hodgkin’s lymphoma following chemotherapy.


Thymidine kinase 1 Non-Hodgkin’s lymphoma Chemotherapy Enhanced chemiluminescent (ECL) dot-blot assay 



This investigation was supported by Sino-Swed Tongkang Bio-Tech Ltd., Shenzhen, China, and by Departments No. 85 and No. 411 at PLA Hospital, Shanghai, China.

Conflict of interest statement

Zhu-Lin Pan, Xing-Ying Ji and Yan-Min Shi report no conflict of interest. Ji Zhou is CEO of SSTK Ltd, and Ellen He and Sven Skog are scientific consulters to SSTK Ltd., the company that produces the TK1 kit. The authors alone are responsible for the content and writing of the paper.


  1. Ferguson RE, Carroll HP, Harris E, Maher ER, Selby PJ, Banks RE (2005) Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 5:566–577CrossRefPubMedGoogle Scholar
  2. Gronowitz JS, Hagberg H, Kallander CFR, Simonsson B (1983) The use of serum deoxythymidine kinase as a prognostic marker and in the monitoring of patients with non-Hodgkin’s lymphoma. Br J Cancer 47:487–495PubMedGoogle Scholar
  3. He Q, Wang N, Skog S, Eriksson S, Tribukait B (1996) Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70:117–124PubMedGoogle Scholar
  4. He E, Mao Y, Wu J et al (2004) Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25:945–953PubMedGoogle Scholar
  5. He Q, Zhang P, Zou L et al (2005) Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumours than its activity. Oncol Rep 14:1013–1019PubMedGoogle Scholar
  6. HengZhi C, Zhou H, Tian NB, He E, Skog S (2008) Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumors. Anticancer Res 28:3897–3908Google Scholar
  7. Kauffman MG, Kelly TJ (1991) Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 11:2538–2546PubMedGoogle Scholar
  8. Ke PY, Chang CF (2004) Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24:514–526CrossRefPubMedGoogle Scholar
  9. Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ (2003) Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. Tumour Biol 24:53–60CrossRefPubMedGoogle Scholar
  10. Poley S, Stieber P, Nussler V et al (1997) Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Res 17:3025–3029PubMedGoogle Scholar
  11. Rehn S, Glimelius B, Sundstrom CA (1991) Comparative study of proliferation-associated parameters in B-cell non-Hodgkin’s lymphoma. Hematol Oncol 9:287–298CrossRefPubMedGoogle Scholar
  12. Sadamori N, Ichiba M, Mine M et al (1995) Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia. Br J Haematol 90:100–105CrossRefPubMedGoogle Scholar
  13. Suki S, Swan F, Tucker S et al (1995) Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymph 18:87–92CrossRefGoogle Scholar
  14. Topolcan O, Lubos Holubec L (2008) The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2:129–140CrossRefGoogle Scholar
  15. Törnevik Y, Ullman BJ, Balzarini J et al (1995) Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human Immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine 5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49:829–837CrossRefPubMedGoogle Scholar
  16. Wu CJ, Yang RJ, Zhou J et al (2003) Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277:157–169CrossRefPubMedGoogle Scholar
  17. Xu XH, Zhang YM, Shu XH et al (2008) Serological thymidine kinase 1 reflects progression of pre-malignant and malignant tumours during therapy. Mol Med Rep 1:705–711Google Scholar
  18. Zhang ZN, Shen D (1998) Diagnosis of blood disease and response criteria. The second version. Beijing Science Press, Beijing, pp 168–349Google Scholar
  19. Zhang F, Li H, Pendleton AR et al (2001) Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev 25:8–15PubMedGoogle Scholar
  20. Zhang J, Jia Q, Zou S et al (2006) Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15:455–461PubMedGoogle Scholar
  21. Zou L, Zhang PG, Zou S, Li Y, He Q (2002) The half-life of cytosolic thymidine kinase in serum by ECL dot bolt: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Marker 17:135–140Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department No. 411PLA HospitalShanghaiChina
  2. 2.Department No. 85Diba Wu HospitalShanghaiChina
  3. 3.Sino-Swed Molecular Bio-Medicine Research InstituteShenzhenChina

Personalised recommendations